KROS Q4 2020 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$13M

Net Income

-$11M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$269M

Total Liabilities

$8M

Stockholders' Equity

$262M

Cash & Equivalents

$266M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	-$2M	+100.0%
Operating Income	-$13M	-$3M	-387.2%
Net Income	-$11M	-$3M	-288.1%